RYTM
Rhythm Pharmaceuticals, Inc. NASDAQ Listed Oct 9, 2017$96.30
Mkt Cap $6.6B
52w Low $55.31
61.3% of range
52w High $122.20
50d MA $87.62
200d MA $98.45
P/E (TTM)
-26.3x
EV/EBITDA
-41.1x
P/B
38.2x
Debt/Equity
1.8x
ROE
-141.3%
P/FCF
-59.6x
RSI (14)
—
ATR (14)
—
Beta
2.14
50d MA
$87.62
200d MA
$98.45
Avg Volume
834.9K
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
222 Berkeley Street · Boston, MA 02116 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BMO | -0.79 | -0.73 | +7.6% | 98.07 | -1.4% | -5.4% | -5.4% | -3.2% | -8.7% | -7.2% | — |
| Nov 4, 2025 | BMO | -0.72 | -0.82 | -13.9% | 104.99 | -2.1% | -5.3% | -5.3% | -6.2% | -4.5% | -7.0% | — |
| Aug 5, 2025 | BMO | -0.66 | -0.75 | -13.6% | 88.57 | -0.7% | +1.6% | +1.6% | +4.4% | +3.9% | +6.5% | — |
| May 7, 2025 | BMO | -0.69 | -0.81 | -17.4% | 64.63 | -1.0% | -6.0% | -6.0% | -11.2% | -8.8% | -12.1% | — |
| Feb 26, 2025 | BMO | -0.69 | -0.72 | -4.3% | 53.32 | +1.6% | -0.6% | -0.6% | +3.0% | -1.7% | -0.2% | — |
| Nov 5, 2024 | BMO | -0.80 | -0.73 | +8.8% | 56.25 | +6.7% | +11.4% | +11.4% | +13.6% | +19.7% | +16.6% | — |
| Aug 6, 2024 | BMO | -0.70 | -0.55 | +21.4% | 44.04 | +1.5% | -1.1% | -1.1% | +4.2% | +2.8% | +1.0% | — |
| May 7, 2024 | BMO | -2.34 | -2.35 | -0.4% | 39.35 | -2.8% | -1.1% | -1.1% | -2.2% | -0.5% | +2.2% | — |
| Feb 22, 2024 | BMO | -0.70 | -0.70 | +0.0% | 44.06 | -0.1% | +2.5% | +2.5% | +4.7% | +4.5% | +0.7% | — |
| Nov 7, 2023 | BMO | -0.76 | -0.76 | +0.0% | 26.95 | +3.7% | +1.7% | +1.7% | -0.0% | +5.6% | +6.3% | — |
| Aug 1, 2023 | BMO | -0.80 | -0.82 | -2.5% | 22.75 | -1.1% | +6.9% | +6.9% | +6.3% | +7.4% | +9.3% | — |
| May 2, 2023 | BMO | -0.71 | -0.92 | -29.6% | 18.74 | +0.6% | -1.2% | -1.2% | -12.2% | -10.9% | -11.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $87.45 | $90.42 | +3.4% | -3.2% | -5.6% | -3.2% | -6.3% | -13.3% |
| Mar 20 | BofA Securities | Maintains | Buy → Buy | — | $90.31 | $96.71 | +7.1% | -3.2% | -6.3% | -8.5% | -6.3% | -9.3% |
| Mar 20 | Citizens | Maintains | Market Outperform → Market Outperform | — | $90.31 | $96.71 | +7.1% | -3.2% | -6.3% | -8.5% | -6.3% | -9.3% |
| Mar 20 | Citigroup | Maintains | Buy → Buy | — | $90.31 | $96.71 | +7.1% | -3.2% | -6.3% | -8.5% | -6.3% | -9.3% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $87.68 | $86.21 | -1.7% | -2.1% | +3.0% | -0.3% | -3.5% | -5.8% |
| Mar 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $90.51 | $89.29 | -1.3% | -3.1% | -5.1% | -0.2% | -3.4% | -6.5% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $90.51 | $89.29 | -1.3% | -3.1% | -5.1% | -0.2% | -3.4% | -6.5% |
| Mar 17 | RBC Capital | Maintains | Outperform → Outperform | — | $90.51 | $89.29 | -1.3% | -3.1% | -5.1% | -0.2% | -3.4% | -6.5% |
| Mar 17 | BofA Securities | Maintains | Buy → Buy | — | $90.51 | $89.29 | -1.3% | -3.1% | -5.1% | -0.2% | -3.4% | -6.5% |
| Mar 17 | Citigroup | Maintains | Buy → Buy | — | $90.51 | $89.29 | -1.3% | -3.1% | -5.1% | -0.2% | -3.4% | -6.5% |
| Mar 17 | Citizens | Maintains | Market Outperform → Market Outperform | — | $90.51 | $89.29 | -1.3% | -3.1% | -5.1% | -0.2% | -3.4% | -6.5% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $90.02 | $88.81 | -1.3% | +1.3% | -2.9% | +0.5% | -2.6% | -4.6% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $92.73 | $90.19 | -2.7% | +2.4% | -3.4% | -1.9% | -1.4% | +0.9% |
| Mar 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $92.73 | $90.19 | -2.7% | +2.4% | -3.4% | -1.9% | -1.4% | +0.9% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $98.07 | $96.66 | -1.4% | -5.4% | -3.2% | -8.7% | -7.2% | -6.7% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $98.07 | $96.66 | -1.4% | -5.4% | -3.2% | -8.7% | -7.2% | -6.7% |
| Feb 27 | Citizens | Maintains | Market Outperform → Market Outperform | — | $98.07 | $96.66 | -1.4% | -5.4% | -3.2% | -8.7% | -7.2% | -6.7% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $99.15 | $103.25 | +4.1% | -1.1% | -6.5% | -4.2% | -9.7% | -8.2% |
| Jan 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $101.63 | $101.60 | -0.0% | +0.9% | +4.3% | +6.6% | +1.2% | +1.7% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $101.63 | $101.60 | -0.0% | +0.9% | +4.3% | +6.6% | +1.2% | +1.7% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $97.46 | $97.40 | -0.1% | +3.7% | +7.6% | +10.6% | +16.3% | +8.8% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $112.14 | $111.68 | -0.4% | +0.7% | +0.2% | +0.1% | -1.9% | +0.4% |
| Dec 17 | Guggenheim | Maintains | Buy → Buy | — | $112.45 | $113.19 | +0.7% | -0.5% | -0.6% | -0.3% | +0.4% | -0.1% |
| Dec 12 | Goldman Sachs | Maintains | Buy → Buy | — | $117.62 | $119.58 | +1.7% | -3.5% | -4.3% | -4.4% | -4.9% | -5.0% |
| Dec 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $117.62 | $119.58 | +1.7% | -3.5% | -4.3% | -4.4% | -4.9% | -5.0% |
| Dec 12 | Citizens | Maintains | Market Outperform → Market Outperform | — | $117.62 | $119.58 | +1.7% | -3.5% | -4.3% | -4.4% | -4.9% | -5.0% |
| Dec 11 | Needham | Maintains | Buy → Buy | — | $104.77 | $113.73 | +8.6% | +12.3% | +8.4% | +7.4% | +7.3% | +6.8% |
| Nov 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $100.30 | $100.00 | -0.3% | -2.7% | -0.4% | -2.4% | -4.4% | -0.9% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $98.49 | $96.55 | -2.0% | +1.8% | -0.9% | +1.4% | -0.6% | -2.6% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $113.74 | $102.46 | -9.9% | -7.7% | -12.5% | -13.4% | -11.8% | -14.2% |
| Oct 17 | Goldman Sachs | Maintains | Buy → Buy | — | $111.18 | $109.98 | -1.1% | -0.8% | +1.1% | -3.6% | -1.8% | -1.9% |
| Oct 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $109.35 | $111.00 | +1.5% | +1.7% | +0.9% | +2.8% | -2.0% | -0.2% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $99.16 | $100.30 | +1.1% | +1.5% | +1.8% | +0.9% | -1.9% | -0.1% |
| Sep 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $96.91 | $98.16 | +1.3% | +2.3% | +2.3% | +3.8% | +4.2% | +3.2% |
| Sep 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $96.91 | $98.16 | +1.3% | +2.3% | +2.3% | +3.8% | +4.2% | +3.2% |
| Sep 24 | Goldman Sachs | Maintains | Buy → Buy | — | $98.70 | $98.74 | +0.0% | -1.8% | +0.4% | +0.5% | +2.0% | +2.3% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.01 | $89.51 | -0.6% | +2.7% | +2.2% | +4.8% | +7.2% | +8.7% |
| Aug 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $88.57 | $87.99 | -0.7% | +1.6% | +4.4% | +3.9% | +6.5% | +8.9% |
| Aug 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $88.57 | $87.99 | -0.7% | +1.6% | +4.4% | +3.9% | +6.5% | +8.9% |
| Aug 6 | Guggenheim | Maintains | Buy → Buy | — | $88.57 | $87.99 | -0.7% | +1.6% | +4.4% | +3.9% | +6.5% | +8.9% |
| Jul 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $90.68 | $91.11 | +0.5% | -1.6% | -2.3% | -3.2% | -3.2% | -3.8% |
| Jul 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $89.00 | $91.80 | +3.1% | +0.0% | -2.6% | +0.2% | +0.4% | +2.7% |
| Jul 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $89.00 | $91.80 | +3.1% | +0.0% | -2.6% | +0.2% | +0.4% | +2.7% |
| Jul 10 | BofA Securities | Maintains | Buy → Buy | — | $89.00 | $91.80 | +3.1% | +0.0% | -2.6% | +0.2% | +0.4% | +2.7% |
| Jul 10 | Leerink Partners | Maintains | Outperform → Outperform | — | $89.00 | $91.80 | +3.1% | +0.0% | -2.6% | +0.2% | +0.4% | +2.7% |
| Jul 9 | Needham | Maintains | Buy → Buy | — | $65.14 | $76.75 | +17.8% | +36.6% | +36.7% | +33.1% | +36.9% | +37.2% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $62.29 | $62.31 | +0.0% | -1.3% | +0.7% | +1.4% | +5.1% | +7.4% |
| May 29 | Stifel | Maintains | Buy → Buy | — | $59.59 | $60.95 | +2.3% | +3.8% | +2.9% | +6.8% | +10.2% | +8.1% |
| May 7 | Needham | Maintains | Buy → Buy | — | $62.71 | $61.07 | -2.6% | +3.1% | -3.2% | -8.5% | -6.0% | -9.4% |
| Apr 10 | BofA Securities | Maintains | Buy → Buy | — | $60.23 | $58.98 | -2.1% | -4.0% | -1.1% | -0.1% | +3.1% | +1.8% |
No insider trades available.
8-K · 2.02
!! High
Rhythm Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Rhythm Pharmaceuticals reported quarterly earnings results; investors should review the full press release in Exhibit 99.1 for detailed financial performance and operational metrics.
May 5
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Rhythmwave's executive leadership change introduces uncertainty about strategic direction and operational continuity, potentially pressuring the stock until investors assess the new leader's qualifications and vision.
Apr 3
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Rhythm Biosciences' obesity treatment gained European regulatory backing, positioning it for EU market approval and significant revenue expansion in the high-growth obesity drug sector.
Mar 26
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Setmelanotide's FDA approval for acquired heterotopic ossification expands RYTM's addressable market and validates its rare disease pipeline, potentially driving significant revenue growth from a previously underserved patient population.
Mar 20
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Rhythm Biosciences' setmelanotide showed mixed clinical trial results with only POMC/PCSK1 patients achieving statistical significance, while other genetic subtypes failed endpoints, likely disappointing investors expecting broader efficacy.
Mar 16
8-K · 8.01
!! High
Rhythm Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Rhythm Pharmaceuticals disclosed material information via press release but the specific announcement details are not provided in this filing summary.
Mar 2
8-K
Rhythm Pharmaceuticals, Inc. -- 8-K Filing
Rhythm Pharmaceuticals reported its 2025 financial results and business update, providing investors with fourth-quarter and full-year performance metrics for the rare neuroendocrine disease-focused biopharmaceutical company.
Feb 26
Data updated apr 26, 2026 11:55pm
· Source: massive.com